Literature DB >> 21642706

Identifying adults at risk of COPD who need confirmatory spirometry in primary care: Do symptom-based questions help?

Kylie Hill1, Richard Hodder, Maria Blouin, Diane Heels-Ansdell, Gordon Guyatt, Roger Goldstein.   

Abstract

Objective To examine the usefulness of a symptom-based case-finding questionnaire (CFQ) and the Medical Research Council (MRC) dyspnea scale in identifying which individuals with known risk factors for chronic obstructive pulmonary disease (COPD) require targeted spirometry in primary care. Design Cross-sectional study. Setting Three community primary care practices in Ontario. Participants Men and women 40 years of age and older with a smoking history of 20 pack-years or more. Main outcome measures We administered a CFQ for the presence of cough, sputum, wheeze, dyspnea, and recurrent respiratory infections (possible range of scores from 0 to 5) and applied the MRC dyspnea scale to assess the severity of COPD (possible range of scores from 1 to 5). Spirometric measures of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were collected, with COPD defined as a postbronchodilator FEV1/FVC of less than 0.7 and FEV1 of less than 80% of the predicted value. Using spirometric data to confirm the diagnosis of COPD, likelihood ratios, pretest and posttest probabilities, and area under a receiver operating characteristic curve were calculated for the total CFQ and MRC scores. Results Scores for the CFQ and MRC dyspnea scale were available for 996 and 829 participants, respectively. The likelihood ratios for a total CFQ score of 3 or higher and an MRC dyspnea score of 4 or 5 were 1.82 (95% confidence interval [CI] 1.48 to 2.22) and 4.22 (95% CI 2.08 to 8.56), respectively. The likelihood ratios for a total CFQ score of 2 or less and an MRC dyspnea score of 1 were 0.75 (95% CI 0.66 to 0.85) and 0.50 (95% CI 0.39 to 0.65), respectively. Area under the receiver operating characteristic curve was 0.62 (95% CI 0.58 to 0.67; P < .001) for the total CFQ scores and 0.64 (95% CI 0.60 to 068; P < .001) for the MRC dyspnea scores. Conclusion In adults with known risk factors, the likelihood of having moderate to severe COPD is increased in those who report 3 or more common respiratory symptoms and marked functional limitation resulting from dyspnea. However, selecting individuals for spirometry based on symptoms alone will identify less than half of those with moderate to severe COPD.

Entities:  

Mesh:

Year:  2011        PMID: 21642706      PMCID: PMC3038833     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  24 in total

1.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994.

Authors:  D M Mannino; R C Gagnon; T L Petty; E Lydick
Journal:  Arch Intern Med       Date:  2000-06-12

2.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care.

Authors:  Kylie Hill; Roger S Goldstein; Gordon H Guyatt; Maria Blouin; Wan C Tan; Lori L Davis; Diane M Heels-Ansdell; Marko Erak; Pauline J Bragaglia; Itamar E Tamari; Richard Hodder; Matthew B Stanbrook
Journal:  CMAJ       Date:  2010-04-06       Impact factor: 8.262

5.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

6.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Authors:  J C Bestall; E A Paul; R Garrod; R Garnham; P W Jones; J A Wedzicha
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

7.  Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study.

Authors:  C P Van Schayck; J M C Loozen; E Wagena; R P Akkermans; G J Wesseling
Journal:  BMJ       Date:  2002-06-08

8.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.

Authors:  Bartolome R Celli; Claudia G Cote; Jose M Marin; Ciro Casanova; Maria Montes de Oca; Reina A Mendez; Victor Pinto Plata; Howard J Cabral
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

9.  Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys.

Authors:  Hana Müllerová; Jadwiga Wedzicha; Joan B Soriano; Jørgen Vestbo
Journal:  Respir Med       Date:  2004-01       Impact factor: 3.415

10.  Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care.

Authors: 
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

View more
  9 in total

1.  Implementation of a targeted screening program to detect airflow obstruction suggestive of chronic obstructive pulmonary disease within a presurgical screening clinic.

Authors:  Chantal Robitaille; Esther Dajczman; Andrew M Hirsch; David Small; Pierre Ernst; Dana Porubska; Mark Palayew
Journal:  Can Respir J       Date:  2015-05-11       Impact factor: 2.409

2.  Pooled Cohort Probability Score for Subclinical Airflow Obstruction.

Authors:  Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Byron C Jaeger; Patricia A Cassano; Paulo H Chaves; David Couper; David R Jacobs; Ravi Kalhan; Robert Kaplan; Donald Lloyd-Jones; Anne B Newman; George O'Connor; Jason L Sanders; Benjamin M Smith; Yifei Sun; Jason G Umans; Wendy B White; Sachin Yende; Elizabeth C Oelsner
Journal:  Ann Am Thorac Soc       Date:  2022-08

3.  Detection of COPD in a high-risk population: should the diagnostic work-up include bronchodilator reversibility testing?

Authors:  Peter Kjeldgaard; Ronald Dahl; Anders Løkke; Charlotte Suppli Ulrik
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-23

4.  Symptom- and Laboratory-Based Ebola Risk Scores to Differentiate Likely Ebola Infections.

Authors:  Shefali Oza; Alieu A Sesay; Neal J Russell; Kevin Wing; Sabah Boufkhed; Lahai Vandi; Sahr C Sebba; Rachael Cummings; Francesco Checchi
Journal:  Emerg Infect Dis       Date:  2017-11       Impact factor: 6.883

5.  Could symptoms and risk factors diagnose COPD? Development of a Diagnosis Score for COPD.

Authors:  Pascale Salameh; Georges Khayat; Mirna Waked
Journal:  Clin Epidemiol       Date:  2012-09-25       Impact factor: 4.790

6.  Respiratory symptoms and peripheral airways disease in a cross-sectional study on a random population sample.

Authors:  Jan Yngve Olofson; Birgitta Houltz; Maria Nilsson Tengelin; Björn Bake
Journal:  BMJ Open       Date:  2012-11-27       Impact factor: 2.692

7.  Impact of risk factors, activities and psychological disorders on the health of patients with chronic obstructive pulmonary disease in China: a cross-sectional study.

Authors:  Lei Zhang; Peian Lou; Yanan Zhu; Peipei Chen; Pan Zhang; Jiaxi Yu; Ning Zhang; Na Chen; Hongmin Wu; Jing Zhao
Journal:  BMC Public Health       Date:  2013-07-02       Impact factor: 3.295

8.  Detection of airflow limitation using a handheld spirometer in a primary care setting.

Authors:  Siew-Mooi Ching; Yong-Kek Pang; David Price; Ai-Theng Cheong; Ping-Yein Lee; Ismail Irmi; Hassan Faezah; Ismail Ruhaini; Yook-Chin Chia
Journal:  Respirology       Date:  2014-04-07       Impact factor: 6.424

9.  Office-Based Case Finding for Chronic Obstructive Pulmonary Disease in Older Adults in Primary Care.

Authors:  Linda Lee; Tejal Patel; Loretta M Hillier; James Milligan
Journal:  Can Respir J       Date:  2016-06-22       Impact factor: 2.409

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.